Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2026-02-20 @ 6:42 PM
Study NCT ID:
NCT03160794
Status:
RECRUITING
Last Update Posted:
2025-02-10
First Post:
2017-05-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 100}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-05-23', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2027-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-02-06', 'studyFirstSubmitDate': '2017-05-18', 'studyFirstSubmitQcDate': '2017-05-18', 'lastUpdatePostDateStruct': {'date': '2025-02-10', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-05-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': '[18F]DCFPyL PET/MR and PET/CT comparison', 'timeFrame': '3 years', 'description': 'To determine concordance and compare performance between \\[18F\\]DCFPyL PET/MR and PET/CT'}, {'measure': 'Concordance of PET-MR/CT finding and histological confirmation of metastatic foci.', 'timeFrame': '3 years', 'description': 'To determine the concordance of PET-MR/CT findings and histological confirmation of metastatic foci.'}, {'measure': 'Biomarker correlates', 'timeFrame': '3 years', 'description': 'To explore blood, urine and tissue biomarker correlates of imaging features and radiotherapy tumour resposnse.'}], 'primaryOutcomes': [{'measure': 'To determine if [18F]DCFPyL PET-MR/CT can identify early oligometastatic disease in patients with a rising PSA and negative staging (CS and BS) after standard-of-care maximal local therapies.', 'timeFrame': '3 years', 'description': 'Endpoint: Detection rates and performance metrics of \\[18F\\]DCFPyL PET-MR/CT in the post-prostatectomy plus adjuvant/salvage RT setting.'}, {'measure': 'To determine if treating PET-MR/CT identified lesions with curative-intent treatment (e.g. stereotactic body radiation therapy or surgery) associated with favorable preliminary measures of clinical performance.', 'timeFrame': '3 Years', 'description': '* Proportion of patients achieving biochemical response: detectable PSA (\\<0.05ng/mL) in 2 consecutive measurements (at least 2 weeks apart) within 6 months of treatment); or \\> 50% PSA decline in 2 separate measurements at least 1 month apart within 6 months of treatment\n* Metabolic \\[18F\\]DCFPyL response rate after treatment\n* Treatment-related toxicities incidence as defined by CTCAE v4.0\n* Time to initiation of salvage ADT after treatment'}], 'secondaryOutcomes': [{'measure': 'Correlation between PSA kinetics and PET imaging parameters', 'timeFrame': '6 months post SABR', 'description': 'To explore the correlation between PSA kinetics and PET imaging parameters (SUV, dynamic data, volumetric studies)'}, {'measure': 'Correlate between tissue biomarker and distant disease', 'timeFrame': '3 years', 'description': 'To explore the correlation between tissue biomarkers from prostatectomy specimen (e.g. genomic signatures) and \\[18F\\]DCFPyL PET/MR-detected distant disease'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Prostate cancer', 'stereotactic ablative radiotherpy', 'PET/MR'], 'conditions': ['Post Prostatectomy']}, 'referencesModule': {'references': [{'pmid': '32327479', 'type': 'DERIVED', 'citation': 'Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, Green D, Finelli A, Hamilton R, Stanescu T, Hussey D, Catton C, Gospodarowicz M, Warde P, Bayley A, Breen S, Vines D, Jaffray DA, Berlin A. [18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open. 2020 Apr 22;10(4):e035959. doi: 10.1136/bmjopen-2019-035959.'}]}, 'descriptionModule': {'briefSummary': 'In the clinical scenario of recurrent prostate cancer (PCa) post local therapy, current standard studies (bone scan and computed tomography) commonly fail to identify the recurrent disease location. In this study the investigator aims to prospectively map recurrent disease with the unique combination of whole-body MR anatomical imaging combined with a new high-sensitivity and PCa-specific PET probe (PSMA-targeted: \\[18F\\]DCFPyL) to provide precise localization information to target disseminated tumor deposits in men presenting with rising PSA after prostatectomy and radiotherapy (maximal local therapies). Moreover, we will consequently treat all identified disease with image-guided stereotactic ablative radiotherapy (SABR), which has shown tantalizing results achieving excellent tumor eradication rates with minimal toxicities. This study is uniquely positioned to enable the discovery of new biomarkers and the correlation of prognostic tests (e.g. genomic signatures) from the initial prostatectomy specimen with the PET-MR/CT imaging results and curative-intent treatment outcomes.\n\nThe significance of the proposed work towards a measurable impact in PCa care is important to emphasize. The study team believes this novel curative-intent approach will transform lives, as opposed to therapies that transiently impact incurable disease stages. Herein, the focus is on patients at the earliest point of the disease spectrum of recurrent PCa after curative-intent treatments. Our hypothesis is that PSMA-targeted \\[18F\\]DCFPyL PET-MR/CT allows earlier detection and localization of defined metastatic targets in these patients, at a stage amenable to image-guided curative-intent therapy.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': '* ECOG performance status of 0-2\n* Absence of significant comorbidities rendering patient nor suitable for curative ablative approaches\n* No history of non-skin malignancy\n* Histological evidence of prostate adenocarcinoma on previous radical prostatectomy.\n* No use of any form of hormonal therapy in the previous 12 months, or intention to start HT at time of enrollment.\n* Normal serum testosterone level ascertained within 4-6 weeks of enrollment\n* Absence of known metastatic disease\n* Radiological studies without evidence of regional or distant metastases: CT abdomen-pelvis and bone scan within previous 3 months\n* Able to lie supine at least 60 minutes to comply with imaging and treatment.\n* Absence of impaired renal function (calculated GFR \\> 30mL/min)\n* Absence of sickle cell disease or other hemoglobinopathies\n* No other medical conditions deemed by the PI to make patient ineligible for PET/MR scanning or SABR\n\nNo contraindications to MRI:\n\n* Subject must weigh \\<136kg (scanner weight limit)\n* Subject must not have pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices not compatible with MRI\n* Prior anaphylactic reaction to gadolinium\n\nRising PSA after maximal local therapies (radical prostatectomy and either adjuvant or salvage radiotherapy):\n\n* Three documented PSA rises, at least 1 month apart from post radiotherapy.\n* PSA value \\>0.1 and \\< 3 ng/mL, within 4-6 weeks of enrollment\n* No use of any forms of ADT in the previous 12 months nor contemplated to be used at time of study enrollment. Salvage ADT to be started when PSA reaches a value of 6.0ng/ml or greater.'}, 'identificationModule': {'nctId': 'NCT03160794', 'briefTitle': 'Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy', 'organization': {'class': 'OTHER', 'fullName': 'University Health Network, Toronto'}, 'officialTitle': 'Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)', 'orgStudyIdInfo': {'id': '16-5532'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '[18F] DCFPyL PET/MRI', 'description': '\\[18F\\] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.\n\nLesions identified through \\[18F\\] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery.', 'interventionNames': ['Diagnostic Test: [18F]DCFPyL PET/MRI scan', 'Radiation: Stereotactic Ablative Radiotherapy']}], 'interventions': [{'name': '[18F]DCFPyL PET/MRI scan', 'type': 'DIAGNOSTIC_TEST', 'description': 'PET/MRI imaging using the radiotracer, \\[18F\\]DCFPyL', 'armGroupLabels': ['[18F] DCFPyL PET/MRI']}, {'name': 'Stereotactic Ablative Radiotherapy', 'type': 'RADIATION', 'description': 'SABR as treatment for lesions identified using \\[18F\\]DCFPyL PET/MRI', 'armGroupLabels': ['[18F] DCFPyL PET/MRI']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'M5G 2M9', 'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Alejandro Berlin, MD', 'role': 'CONTACT', 'email': 'alejandro.berlin@rmp.uhn.ca', 'phone': '416-946-4501', 'phoneExt': '5813'}, {'name': 'Alejandro Berlin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Princess Margaret Cancer Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'centralContacts': [{'name': 'Alejandro Berlin, MD', 'role': 'CONTACT', 'email': 'alejandro.berlin@rmp.uhn.ca', 'phone': '416-946-4501', 'phoneExt': '2126'}], 'overallOfficials': [{'name': 'Alejandro Berlin, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Princess Margaret Cancer Centre - University Health Network'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Health Network, Toronto', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}